DETERMINATION OF SERUM INTERLEUKIN-36 ALPHA, BETA, GAMMA AND INTERLEUKIN-17 LEVELS IN PATIENTS WITH MULTIPLE MYELOMA

Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by bone marrow infiltration of clonal plasma cells. Today, there is no treatment for obtaining a complete cycle for MM. IL-36 is a cytokine composed of three agonists named alpha, beta, and gamma. Its increase in inflammation has been proven in the literature. It is also reported that IL-17 plays a role in some rheumatologic and malignant diseases together with inflammation. 
 The aim of the study is to figure out the roles, if any, of IL-36 and IL-17 in the pathogenesis of multiple myeloma depending on their known physiology and to contribute to the literature to find new treatment options.
 33 newly diagnosed MM patients who had never received any treatment and 33 healthy volunteers were included in the study. Basic laboratory parameters and interleukin levels in myeloma patient group and healthy group were included in the study.
 In the study, it was found that IL-36 alpha, beta, gamma, and IL-17 levels were statistically significantly lower in the disease group when compared to the healthy group. A negative correlation was found between IL-17 measurement and beta-2 microglobulin. Therefore, it was thought that IL-17 may be a marker to predict prognosis.
 In conclusion, we think that IL-36 and IL-17 may play a role in the etiopathogenesis of myeloma and IL-36 alpha and IL-17 may be associated with prognosis. However, there is a need for more comprehensive studies.